Drug Landscape ›
Zofran 8 mg ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 47
Most-reported reactions
Dyspnoea — 7 reports (14.89%) Infusion Related Reaction — 6 reports (12.77%) Nausea — 6 reports (12.77%) Diarrhoea — 5 reports (10.64%) Erythema — 5 reports (10.64%) Flushing — 5 reports (10.64%) Asthenia — 4 reports (8.51%) Chest Discomfort — 3 reports (6.38%) Deep Vein Thrombosis — 3 reports (6.38%) Febrile Neutropenia — 3 reports (6.38%)
Source database →
Zofran 8 mg in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Zofran 8 mg approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Zofran 8 mg in United States?
Medical University of Gdansk is the originator. The local marketing authorisation holder may differ — check the official source linked above.